Search Results
Results for: ""
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics announced that the first patient has been dosed in the CALM-CAH Phase 3 trial evaluating investigational candidate atumelnant, a...
READ MORE →Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards...
READ MORE →Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Crinetics announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic or...
READ MORE →Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
Crinetics announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, randomized, double-blind, placebo-controlled...
READ MORE →Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 37,675 shares of its common stock and granted an...
READ MORE →Webcast: Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results
Crinetics company management will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.
READ MORE →Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports third quarter 2025 financial results and provided a business update on November 6, 2025 at 4:30PM ET.
READ MORE →NANETS 2025: Reimagining Treatment for Carcinoid Syndrome
Tom BeveridgeGlobal Product Lead, Paltusotine for Carcinoid Syndrome For individuals living with carcinoid syndrome (CS), a condition caused by neuroendocrine...
READ MORE →Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid...
READ MORE →Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics grants non-qualified stock option awards to purchase an aggregate of 78,975 shares of its common stock and granted an...
READ MORE →Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
